Opinion & analysis

Moving Medical Affairs To The Pharma Forefront

Senior medical affairs officials sat down at a roundtable discussion facilitated by the Boston Consulting Group to discuss the role of medical affairs along the pharma value chain. Take a look at the outcome of this discussion and explore the role and challenges of medical affairs in pharma.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

Moving Medical Affairs To The Pharma Forefront

Bye-Bye QSR? FDA May Swap Its Quality System Regulation For ISO 13485 ‘In The Coming Years,’ Official Says

What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’

Anti-Aging Cosmetics Or Unlawfully Marketed Drugs? Two Federal Court Cases To Watch

The Oncology Burden Of Proof: Learning From The PD-1 Market

Gene Therapy’s Next Big Challenge: Manufacturing

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework

GSK’s Head Of Artificial Intelligence Unveils R&D Goals

Pharma’s New R&D Models: Federating Innovation

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s

Defying FDA: Shanghai Lab Gets Warning Letter But Won’t Relent

Culture Change At GSK: ‘We’re Doing What We Said We’d Do’

Six Key New Commission Documents Relating To EU Directives And New Regulations

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Mortality Signal For Pfizer’s Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class

Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage

Pharma Intelligence Report Store Article: Collection Cybersecurity

DECIEM, Truly ‘The Abnormal Beauty Company,’ Faces Uncertain Future

Notified Bodies And EU Industry Voice Separate, But Aligned Frustrations Over Slow Progress In NB Designations

R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking

Innovations In Market Access: The Will, But Not The Way?

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy

Into 2019: Risk, Uncertainty And A Return To Product Focus

Want To Add A Drug Coating To Your Device? Check FDA’s New Guide

The Emergence Of IO

Four Rules For Being A Consistent US FDA Reviewer From Peter Stein